Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138
An Open Letter to Shareholders regarding a Reverse Stock Split
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
TransCode Therapeutics Reports 2023 Results; Provides Business Update
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
TransCode and Akribion Report Progress Developing CRISPR-Derived Technology
TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode™s RIG-I Agonist Immunotherapeutic
Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders™ Equity Requirement, Continued Listing on the Nasdaq Stock Market